XUHC:F:F-Xtrackers (IE) Public Limited Company - Xtrackers MSCI USA Health Care UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 52.56

Change

-0.06 (-0.11)%

Market Cap

USD 0.85B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-03 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

+0.07 (+0.27%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

+0.11 (+0.22%)

USD 113.22B
SXR8:F iShares Core S&P 500 UCITS ETF..

-1.30 (-0.25%)

USD 83.51B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

+0.13 (+0.25%)

USD 77.76B
FRCJ:F UBS MSCI Japan Socially Respon..

+0.05 (+0.21%)

USD 73.13B
EUNL:F iShares Core MSCI World UCITS ..

-0.07 (-0.07%)

USD 72.04B
SXRZ:F iShares VII PLC - iShares Nikk..

-0.45 (-0.20%)

USD 56.29B
XDNY:F Xtrackers MSCI Japan ESG Scree..

+0.04 (+0.28%)

USD 54.81B
VUAA:F Vanguard S&P 500 UCITS Acc

N/A

USD 51.63B
VUSA:F Vanguard Funds Public Limited ..

-0.24 (-0.25%)

USD 51.63B

ETFs Containing XUHC:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.73% 56% F 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.73% 53% F 55% F
Trailing 12 Months  
Capital Gain 8.29% 54% F 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.29% 52% F 54% F
Trailing 5 Years  
Capital Gain 65.34% 86% B+ 78% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 65.34% 86% B+ 65% D
Average Annual (5 Year Horizon)  
Capital Gain 10.80% 85% B 77% C+
Dividend Return 10.80% 83% B 71% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.74% 57% F 80% B-
Risk Adjusted Return 100.55% 98% N/A 97% N/A
Market Capitalization 0.85B 71% C- 56% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike